SPATA13 Safe Harbor Locus for Stable Transgene Integration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current transgenic techniques face challenges with random transgene integration, leading to issues like insertional mutagenesis and gene silencing, and there is a lack of validated 'safe harbor' genome loci for stable and predictable transgene expression, especially for therapeutic applications.
Innovation Solution
Identification of a specific genomic locus within the SPATA13 gene on chromosome 13q12.12 as a safe and stable insertion site for transgenes, allowing for site-specific integration using CRISPR or other site-specific technologies, enabling predictable and stable expression of transgenes in cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If random insertion method is used, then transgene integration is simple, but insertional mutagenesis and gene silencing occur
Solution Approach 1:
The patent uses a specific genomic locus (AAVS1 on chromosome 19) as an intermediary safe harbor site for transgene integration. This locus serves as a mediator between the transgene and the genome, providing a controlled integration point that avoids random insertion risks while maintaining integration efficiency. The AAVS1 locus is specifically designed to accept transgenes without causing insertional mutagenesis or gene silencing.
2Manufacturing precision
If site-specific insertion is used, then transgene integration precision is improved, but the number of validated safe harbor loci is insufficient
Solution Approach 1:
The patent promotes the AAVS1 locus as a universal safe harbor site that can be used across multiple cell types and for various transgene applications. This single validated locus provides multi-functional utility, serving as a versatile integration site for different therapeutic and research purposes, thereby addressing the limitation of having insufficient validated loci.
3Ease of manufacture
If transgene is inserted at arbitrary location, then integration is easier, but expression level is unpredictable
Solution Approach 1:
The patent changes the chromosomal location parameter by directing transgene integration to a specific genomic coordinate (AAVS1 on chromosome 19). This parameter change from random to fixed location ensures predictable expression levels while maintaining integration efficiency through established homing endonuclease technology.
4Adaptability or versatility
If multiple safe harbor loci are validated, then versatility of site-specific insertion is improved, but validation time and resources increase
Solution Approach 1:
The patent performs preliminary validation of the AAVS1 locus beforehand, establishing it as a pre-approved safe harbor site. This preliminary action allows the locus to be readily used for multiple applications without requiring repeated validation processes, thereby reducing time and resource losses while maintaining versatility.
Data Source
AI summary
This invention relates to genetic engineering, in particular to an insertion site for a transgene, cells comprising a transgene or other modification at that insertion site, vectors for targeting that insertion site, and methods for creating transgenic cells by insertion or other modification at that site. The insertion site, or “safe harbour locus”, is identified within the SPATA13 gene on human chromosome 13q12.12. Mammalian cells comprising a genetic modification within the SPATA13 gene on chromosome 13q12.12 are described, wherein the modification may be an insertion such as an integrated transgene. Nucleic acid molecules able and adapted to guide the insertion of a transgene to that insertion site are also described. These cells or nucleic acids may be useful in therapy.